Efavirenz: a review.

@article{Vrouenraets2007EfavirenzAR,
  title={Efavirenz: a review.},
  author={Saskia M. E. Vrouenraets and Ferdinand W. N. M. Wit and Jacqueline van Tongeren and Joep M. A. Lange},
  journal={Expert opinion on pharmacotherapy},
  year={2007},
  volume={8 6},
  pages={851-71}
}
Efavirenz is a non-nucleoside reverse transcriptase inhibitor that in most treatment guidelines is recommended to be taken combined with two nucleoside analogue reverse transcriptase inhibitors, as a preferred first-line regimen for the treatment of HIV-1 infection. The antiretroviral efficacy of efavirenz-based combination regimens is good, as has been demonstrated in many clinical trials. Efavirenz has a long plasma half-life, which allows for once-daily dosing, but, as a consequence of this… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
23 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 23 extracted citations

Similar Papers

Loading similar papers…